- 52-week Phase 2 data from AMETHYST study of litifilimab in CLE
- 27.2% of patients on litifilimab from start achieved CLA-IGA-R 0/1 at Week 52 (vs 19.0% at Week 24)
- 28.8% achieved CLASI-70 at Week 52 (vs 21.7% at Week 24)
- Safety: 3.4% serious AEs during extended treatment; most common AEs nasopharyngitis, influenza, arthralgia
- Data presented at EADV 2026 Congress
- Biogen released 52-week Phase 2 data from the AMETHYST study of litifilimab in cutaneous lupus erythematosus (CLE). The data showed continued improvement in skin clearance through Week 52, with 27.2% of patients on litifilimab from the start achieving clear or almost clear skin (CLA-IGA-R 0/1), up from 19.0% at Week 24. On the CLASI-70 measure, 28.8% achieved a 70% or greater reduction in disease activity at Week 52, versus 21.7% at Week 24. Patients who crossed over from placebo to litifilimab at Week 24 saw rapid onset within four weeks, with 33.7% reaching clear or almost clear skin by Week 52. Safety was consistent with prior studies; no new signals.
The headline and the read are open. The reasons are one free account away, on every story.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
BORSAPLUSWhy it matters · Bull and bear case · Reaction against SPY and the sector · What to watch
Create a free account · no card 
